Sign In
Buy CFRX
$0.0500
+0 (+0%)
At Close: Mar 04, 2024
ContraFect Invited to Present New Research Data From Its Pipeline of Direct Lytic Agents at World Microbe Forum
07:30am, Thursday, 17'th Jun 2021
YONKERS, N.Y., June 17, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLA
Exebacase showed the potential to be used in patients with chronic Staphylococci prosthetic knee infection (PKI) to reduce symptoms and improve function
ContraFect Reports First Quarter 2021 Financial Results and Provides Business Update
07:30am, Friday, 14'th May 2021
Interim futility analysis from the Phase 3 DISRUPT study of exebacase evaluating treatment superiority is anticipated in H2 2021
ContraFect Announces Issuance of Composition of Matter Patent for CF-370 by the United States Patent and Trademark Office
07:30am, Monday, 03'rd May 2021
YONKERS, N.Y., May 03, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs
ContraFect Invited to Present at the Inaugural Anti-Infectives Drug Development Summit
06:30pm, Thursday, 15'th Apr 2021
YONKERS, N.Y., April 15, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DL
ContraFect Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
07:30am, Tuesday, 30'th Mar 2021
Exebacase Phase 3 DISRUPT study enrollment ongoing in patients with Staph aureus bloodstream infections; results from interim futility analysis anticipated in H2 2021
YONKERS, N.Y., March 22, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on discovering and developing direct lytic agents for the treatm
ContraFect Corporation Announces Proposed Public Offering of Common Stock
04:01pm, Wednesday, 17'th Mar 2021
YONKERS, N.Y., March 17, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on discovering and developing direct lytic agents for the treatm
Why ContraFect, Evoke, Altimmune, Novavax Are Moving Friday
11:32am, Friday, 12'th Mar 2021
Among the health care stock movers Friday are ContraFect Corporation (NASDAQ: CFRX), Evoke Pharma, Inc. (NASDAQ: EVOK), Altimmune, Inc. (NASDAQ: ALT) and Novavax, Inc. (NASDAQ: NVAX). Here's why the
CFRX Stock Price Increases Over 15% Pre-Market: Why It Happened
07:32am, Friday, 12'th Mar 2021
The stock price of ContraFect Corp (NASDAQ: CFRX) increased by over 15% pre-market. This is why it happened.
ContraFect And Its Narrowed Phase 3 Approach
11:20am, Wednesday, 10'th Mar 2021
ContraFect And Its Narrowed Phase 3 Approach
ContraFect Reports Third Quarter 2020 Financial Results and Provides Business Update
08:33am, Friday, 13'th Nov 2020
CARB-X and Cystic Fibrosis Foundation grant s provide significant additional funding to advance CF-370 for Pseudomonas aeruginosa infections
El Málaga marca, aguanta, no sentencia y sufre ante un buen Sporting
11:10pm, Thursday, 22'nd Oct 2020
Los primeros minutos fueron de tanteo, con una ocasión del conjunto asturiano y gol anulado del delantero serbio Nikola Cumic
